Top Markets
Coin of the day
Silverback Therapeutics, Inc. Silverback Therapeutics, Inc.

Silverback Therapeutics, Inc.

SBTX
Rank in Stocks #12783
Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to... Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to devising tissue-specific drug candidates aimed at addressing chronic viral infections, various cancers, and other significant medical conditions. Among its pipeline, SBT8230 stands out as a treatment for chronic hepatitis B virus, working by stimulating an antiviral immune response through the precise activation of TLR8 within the liver. The company was founded in 2016 and maintains its principal offices in Seattle, Washington.
Share Price
$5.87
Last synced: 2022-11-08
Market Cap
$550.43M
Change (1 day)
1.03%
Change (1 year)
0.00%
Country
US
Trade Silverback Therapeutics, Inc. (SBTX)

Category

P/B ratio for Silverback Therapeutics, Inc. (SBTX)
P/B ratio as of 2026 TTM: 0
According to Silverback Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Silverback Therapeutics, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH